GNT is developing new plant-based, sustainable EXBERRY color solutions for food and drink using unique fermentation technologies.
The company has been creating EXBERRY colors from fruit, vegetables, and plants since its foundation in 1978. It is now expanding into fermentation for the first time to increase innovation and sustainability in its plant-based solutions.
Producing colors through fermentation allows for improved functionality as well as highly efficient and sustainable year-round production. Once the raw materials have been cultivated, they can be scaled up in larger bioreactors for industrial production. This phase involves maintaining optimal conditions to ensure high biomass yield and pigment concentration.
To deliver on its aims, GNT has chosen to collaborate with Plume Biotechnology, a UK-based start-up focused on innovation in fermentation science and bioprocessing for natural colors.
“As pioneers in plant-based colors, innovation has always been crucial to GNT and we’re fully committed to delivering cutting-edge solutions for our customers. As a family business, we understand the importance of acting responsibly and ensuring we are truly sustainable. This partnership with Plume will help us add new, futureproof options to our plant-based EXBERRY portfolio," said Frederik Hoeck, GNT Group’s managing director.
The collaboration is designed to help GNT expand the options in its plant-based EXBERRY® portfolio while meeting its sustainability ambitions. In 2022, GNT announced 17 targets to optimize its environmental and social impacts by the end of the decade
“The rapid evolution of fermentation-based technologies is providing unprecedented opportunities within the realms of natural colors. Plume is passionate about translating these cutting-edge technological developments into healthy, exciting, and sustainable products for consumers. In GNT, we have found the perfect strategic partner with a shared commitment to delivering excellent products whilst keeping sustainability at the heart of everything we do," said Thomas Burns, CEO at Plume Biotechnology.
